Date: 2017-02-28
Type of information: Nomination
Compound:
Company: Crispr Therapeutics (Switzerland - USA - MA)
Therapeutic area:
Type agreement: nomination
Action mechanism:
Disease:
Details: • On February 28, 2017, Crispr Therapeutics announced the appointment of Jon Terrett, as Head of Immuno-Oncology Research and Translation. Dr. Terrett brings to Crispr Therapeutics an impressive track record for discovering and progressing a number of immuno-oncology drug candidates into the clinic. Prior to joining Crispr Therapeutics, Dr. Terrett was the Vice President of oncology discovery for CytomX, a U.S.-based biotechnology company focused on developing drugs to treat different types of cancer. In addition, Dr. Terrett has held various R&D leadership roles in biopharma, including serving as the Chief Scientific Officer at Oxford Biotherapeutics, and as a director at various biotechnology companies including Medarex, CellTech and Oxford Glycosciences. Dr. Terrett earned a B.S. in genetics at the University of Sheffield and a doctorate in genetics at the University of Nottingham.
Financial terms:
Latest news:
